/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained drug delivery moving toward clinical use



    Sustained delivery is an idea whose time is coming, but not quite yet. Only four sustained release ophthalmic formulations have been approved anywhere and most are not available in the United States. Michael O’Rourke, president and CEO of GrayBug, would like to change that.

    “We can tailor microparticle and nanoparticle platforms with delivery times from days to months, depending on the need,” O’Rourke said. “We have seen a 30% to 50% increase in drug in target tissues compared to topical delivery for up to 115 days and very good long-term lowering of IOP in animal models.”

    The miniature particles are extremely well tolerated, he added. In rabbit tests, particle injections induced inflammation similar to saline injections and significantly less than convention PLGA particles.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results